secwatch.observer — SEC 8-K summary
======================================

Issuer:     VACCINEX, INC. (VCNX)
CIK:        0001205922
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001193125-23-241942
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccinex presents pepinemab data at conferences; AD study completion expected Jun 2024, cancer ORR doubled
--------------------------------------------------------------------------------

- Pepinemab presentations at Keystone Symposia (Oct 1-5) and CTAD (Oct 24-27) featuring AD and cancer data.
- SIGNAL-AD phase 1/2a fully enrolled; last patient completes treatment by June 2024; key endpoints FDG-PET, CDR-SB, ADAS-Cog13.
- KEYNOTE-B84: In PD-L1 low HNSCC (CPS<20), ORR 21.1% and median PFS 5.79 months, ~2x historical checkpoint monotherapy.
- Combination with KEYTRUDA induces organized lymphoid structures correlated with disease control and PFS (p=0.0056).
- Vaccinex and Merck in preliminary stages of potential extension study adding chemotherapy to pepinemab+KEYTRUDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1205922/000119312523241942/0001193125-23-241942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1205922/000119312523241942/d481466d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-241942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer